Photo of Jason E. Faris, MD

Jason E. Faris, MD


Accepting New Patients





Centers & Specialties

Cancer Center

Clinical Interests
  • Gastrointestinal Cancers
  • New therapeutics for patients with GI Cancers
Medical Education
  • MD, Johns Hopkins University School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Dana Farber Cancer Institute
Board Certifications
  • Internal Medicine
  • Medical Oncology
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Medicaid
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile


Dr. Jason Faris attended medical school at the Johns Hopkins School of Medicine.  Following graduation, he completed internship and residency at the Massachusetts General Hospital (MGH), and fellowship training at the Dana Farber Cancer Institute. Midway through fellowship, Dr. Faris served as a Chief Resident in the Department of Medicine at MGH.  Dr. Faris currently is an attending physician with the GI Cancer program at the MGH Cancer Center, and is interested in the evaluation of new therapeutics for GI cancers.  Dr Faris is the principal investigator for several clinical trials open to patients with GI Cancers.  

Edit Profile

Research & Publications


View my most recent publications at PubMed

Faris JE, Wo JY.  The controversial role of chemoradiation for patients with locally advanced pancreatic cancer.  Oncologist 2013; 18(9): 981-85.

Faris JE, Ryan DP. Controversy and consensus on management of patients with pseudomyxoma peritonei. 
Curr Treat Options Oncol 2013;14(3): 365-373.

Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in Locally Advanced Pancreatic Cancer. Oncologist. 2013; 18(5):543
Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci. 2012 Jul; 19(4):326-36

Faris, JE, Ryan DP. Biomarker-Driven Therapy in the Neoadjuvant Treatment of Colorectal Liver Metastases. Curr Colorectal Cancer Rep 2012; 8(2):143-151

Faris JE, Ryan DP. Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wt disease. J Clin Oncol. 2012 Apr 20; 30(12):1255-7

Faris JE, Arnott J, et al. A phase 2 study of oral MKC-1. Invest New Drugs. 2012 Aug; 30(4):1614-20.

Faris JE, Smith MR. Metabolic sequelae associated with ADT for prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2010 Jun; 17(3):240-6

Faris JE, Michaelson MD. Targeted therapies: Sunitinib vs interferon-alpha in metastatic RCC. Nat Rev Clin Oncol. 2010 Jan; 7(1):7-8

Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol. 2009 Feb; 7(2):125-33

Faris JE, Moore AF, Daniels GH. Sunitinib-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 2007 Nov; 17(11):1147-9.

Edit Profile


55 Fruit Street
Boston MA, 02114-2696
Phone: 617-724-4000
Fax: 617-726-0452

Edit Profile

Back to Top